A prospective, multicenter, controlled, real-world clinical study of Tiaoshen Xuanluo Changmo formula combined with abdominal external application to improve endometrial blood flow after TCRA

Yunnan Provincial Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1) Married female, aged 20-40 (including 20 and 40);
•2) Body mass index (BMI) 18-26 (kg/m2) (including boundary value);
•3) Meet the diagnostic criteria of Western medicine IUA and traditional Chinese medicine kidney deficiency and blood stasis syndrome;
•4) After TCRA;
•5) Good compliance, willing to participate in and cooperate with researchers to complete the study;
•6) The nature, significance, possible benefits, possible inconvenience and potential risks and discomfort of the trial have been understood in detail before the trial, and they have voluntarily participated in the clinical trial and signed a written informed consent.

•1) Those who do not meet the above diagnostic criteria;
•2) Those aged <20 years or >40 years;
•3) Body mass index (BMI) < 18 or > 26 (kg/m2);
•4) Adhesion of cervical canal;
•5) Menorrhagia caused by other diseases;
•6) Congenital malformation of reproductive organs (such as uterine mediastinum, residual horn uterus, etc.);
•7) Organic diseases of reproductive system (such as tuberculosis of reproductive system);
•8) Patients with serious cardiovascular, cerebrovascular, liver, kidney and other major organ diseases;
•9) Those who have taken hormone or similar traditional Chinese medicine treatment 1 month (30 days) before administration;
•10) Those who are known to be allergic to the study drug (including the excipients of the study drug) or its analogues, or those with allergic constitution (such as those who are allergic to two or more drugs, food and pollen).

发起方

Yunnan Provincial Hospital of Traditional Chinese Medicine